Published:
Axial Biotech appoints new Vice President of Strategic Initiatives
SALT LAKE CITY, Sept. 5 /PRNewswire/ -- Axial Biotech Inc., a company
focused on the development of molecular diagnostic and motion preserving
technologies in the spine care market, announced today that Joe Ross has
joined the executive management team as the company's new Vice President of
Strategic Initiatives.
In this new role, Ross will oversee Axial Biotech's global efforts to
identify, evaluate, and pursue new diagnostic opportunities and will help to
coordinate the company's long-term business strategy, solicit investment
backing, and expand key development partnerships.
John Climaco, President and CEO of Axial Biotech, stated, "As we prepare
for the commercial introduction of our DNA based prognostic test for
Adolescent Idiopathic Scoliosis with our partners at DePuy Spine, we look
forward to building on our successful research, and developing additional
diagnostic tools to meet the clinical needs of today, and those anticipated in
the future. Mr. Ross is uniquely qualified to drive this effort given his vast
industry knowledge and experience, and successful track record of working
closely with physician thought leaders to develop innovative clinical
solutions."
Ross brings with him more than 12 years of experience in orthopedic
medical devices and biologics. Prior to his most recent position as Vice
President of Global Marketing for Stryker Biotech, Ross worked 11 years with
the DePuy Spine division of Johnson and Johnson Corporation in roles of
increasing responsibility including Worldwide Vice President for New Business
Development. Ross has led numerous successful product and business development
efforts and has been granted multiple U.S. patents. He is a graduate of the
University of Notre Dame and Troy State University. He has also served five
years as an officer inthe United States Navy.
"I am thrilled to be joining the Axial Biotech team of accomplished
researchers, clinicians and business professionals," said Ross. "The
technologies being developed by Axial Biotech have the potential to transform
not only the diagnostic process, but the identification and timing of the
appropriate therapy, and ultimately to drive the development of revolutionary
new treatments for multiple diseases of the spine. This is transformational
technology that will significantly enhance patient outcomes and quality of
life."
About Axial Biotech
Axial Biotech, Inc. develops molecular diagnostic assays and motion
preservation technologies for common spinal diseases and disorders. Axial has
developed the first DNA based prognostic test for Adolescent Idiopathic
Scoliosis. Axial is accredited by the College of American Pathologists (CAP)
and is certified to comply with the Clinical Laboratory Improvement Amendments
(CLIA). Founded in 2002, Axial is based inSalt Lake City, Utah.
SOURCE Axial Biotech, Inc.
Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze,
Daily NewsTags: ,HEA,MTC,BIO,PER,UT-Axial-Biotech-Inc.
_ _Is your favorite bookmark site missing?
Ask for it.
Search News
Daily News
